Patents Examined by Thomas Cunningham
  • Patent number: 5583031
    Abstract: The invention features an isolated sample of mammalian class II major histocompatibility heterodimers which are membrane-associated or in soluble form, and which are capable of binding added antigenic peptide; methods for producing large amounts of the soluble or membrane-associated histocompatibility protein by expression of DNA encoding the .alpha. and .beta. polypeptides; and methods for loading these heterodimers with any desired antigen.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: December 10, 1996
    Assignee: President and Fellows of Harvard College
    Inventor: Lawrence J. Stern
  • Patent number: 5538724
    Abstract: Methods and compositions are described for modulating trafficking of leukocytes to endothelial cells involving the binding of homing receptors and addressins. Particularly, compositions are provided which can inhibit the interaction between the homing receptor and addressin or provide for directing specific molecules associated with diagnosis or treatment, where the molecules bind to the addressins.
    Type: Grant
    Filed: December 19, 1991
    Date of Patent: July 23, 1996
    Assignee: The Board of Trustees for the Leland Stanford Junior Univ.
    Inventors: Eugene C. Butcher, Philip R. Streeter, Ellen L. Berg
  • Patent number: 5516515
    Abstract: Two distinct alpha interferon receptor proteins have been separated and partially purified by antigen affinity chromatography and SDS-PAGE. These proteins are potentially useful as therapeutic agents. Antibodies against these proteins are potentially useful as diagnostic and therapeutic agents.
    Type: Grant
    Filed: May 3, 1990
    Date of Patent: May 14, 1996
    Assignee: Interferon Sciences, Inc.
    Inventors: Laura C. Vellucci, Steven R. Scott, Mei-June Liao, Douglas Testa
  • Patent number: 5500215
    Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: March 19, 1996
    Assignee: The Biomembrane Institute
    Inventor: Sen-itiroh Hakomori
  • Patent number: 5422428
    Abstract: Antigenic surface proteins from the intraerythrocytic merozoite stage of Babesia bigemina have been isolated using cell fusions and monoclonal antibodies produced thereby. The gene encoding a 58 kD surface protein has been identified and the DNA sequence determined and compared with sequences of other known merozoite proteins. Immunization of mammals, such as bovines, with purified isolates induces an immunological response that is effective to reduce pathological effects of babesiosis induced by Babesia bigemina. Diagnostic kits using monoclonal antibodies and antigenic surface proteins of Babesia bigemina are also disclosed.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: June 6, 1995
    Assignee: Washington State University
    Inventors: Travis C. McGuire, Terry F. McElwain, Lance E. Perryman, William C. Davis
  • Patent number: 5403919
    Abstract: Novel antibodies that recognize endothelial cell surface molecules and block leukocyte extravasation are provided. These antibodies recognize tissue-specific endothelial cell surface molecules and block lymphocyte migration from the blood into tissues such as mucosal lymphoid organs and peripheral lymph nodes. Novel endothelial cell surface proteins involved in leukocyte extravasation and having a molecular weight of approximately 58,000 to 69,000 daltons and express a tissue-specific determinant are also described. The antibodies are used in an immunotherapeutic method to treat individuals having a disease or inflammation-associated pathology in which leukocyte extravasation plays a role.
    Type: Grant
    Filed: March 3, 1993
    Date of Patent: April 4, 1995
    Assignee: Board of Trustees of the Leland Stanford Junior University Stanford University
    Inventor: Eugene C. Butcher
  • Patent number: 5395614
    Abstract: Protective Plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens HRPII and SERP, the preparation and use thereof.The invention relates to hybrid proteins composed of part-sequences of the malaria antigens HRPII and SERP. The HRPII sequence has already proven protective in the monkey model (EP-A2-0 315 085), where a C-terminal region of 189 amino acids has been used in the present invention in the same way as in the preceding protection experiment. SERP was identified with the aid of an antiserum against a protective protein band (EP-A1-0 283 882); the part-sequence used (amino acids (AA) 631-892 or 630-764) contains at least two T-cell epitopes (Roussilhon et al. (1990), Immunol. Letters 25, 149-154). In preferred embodiments, further T-cell epitope-containing regions of other P. falciparum proteins such as merozoite surface antigen I (MSA I or else "195 kd antigen"), amino acids from 100 to 300, are incorporated (Crisanti et al. (1988), Science 240, 324-326).
    Type: Grant
    Filed: November 16, 1993
    Date of Patent: March 7, 1995
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernhard Knapp, Erika Hundt, Burkhard Enders, Hans Kupper
  • Patent number: 5393523
    Abstract: Recombinant histidine-rich protein of Plasmodium falciparum, its preparation and use. It was possible, by screening two different Plasmodium falciparum cDNA gene banks with an antiserum against a 41 kD protein and by cross-hybridization with the insert DNA of a clone obtained therewith, to isolate a gene which codes for a Histidine-Alanine-rich protein (HRP-II). This protein protects aotus monkeys from infection with P. falciparum and is thus a suitable constituent of a malaria vaccine.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: February 28, 1995
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernard Knapp, Erika Hundt, Burkhard Enders, Hans Kupper
  • Patent number: 5389530
    Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.
    Type: Grant
    Filed: July 27, 1993
    Date of Patent: February 14, 1995
    Assignee: The Biomembrane Institute
    Inventor: Sen-itiroh Hakomori
  • Patent number: 5385888
    Abstract: Methods and compositions are provided for regulating surface membrane receptor response by modulating the interaction between an MHC Class I antigen and the surface membrane receptor. Various techniques may be employed for enhancing or reducing the interaction between the Class I antigen and surface membrane receptor, e.g., enhancing production of the Class I antigen.
    Type: Grant
    Filed: May 3, 1993
    Date of Patent: January 31, 1995
    Assignee: The Regents of the University of California
    Inventors: Robert S. Goodenow, Lennart Olsson
  • Patent number: 5374520
    Abstract: Assay methods and kits for detecting and quantifying anti-Epstein-Barr Virus ("EBV") antibodies in a sample. The methods comprise contacting samples with a free or immobilized synthetic antigenic EBV polypeptide that is recognized by human antibodies and detecting or quantifying immunocomplex formation. The polypeptides described are the carboxy-terminated one-third of the EBV Nuclear Antigen encoded by the EBV Bam H1 K-fragment (plasmid pNAK28), a 46-55 kDa EBV Early Antigen encoded by the 4340 base pair Bcl 1 to Bam H1 restriction fragment within the EBV Bam H1 M-fragment (plasmid pEAD), and an EBV viral capsid antigen. Bacterially synthesized fusion proteins are recognized by human anti-EBV antibodies. The assay method is diagnostic for infectious mononucleosis, chronic mononucleosis, Burkett's lymphoma and monopharyngeal carcinoma.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: December 20, 1994
    Assignee: The Johns Hopkins University
    Inventor: Gregory Milman
  • Patent number: 5348740
    Abstract: This invention relates to polypeptide antigens of T.ovis suitable for use in vaccines to protect ruminants against infection by cestode parasites. The antigens are preferably obtained by expression of DNA coding therefor in a recombinant host cell. Aspects of the invention include DNA encoding the antigens, vectors containing the DNA and hosts which express the antigens.The invention also provides antibody and DNA probes for use in identifying protective antigens of cestode parasites other than T.ovis.
    Type: Grant
    Filed: March 16, 1992
    Date of Patent: September 20, 1994
    Assignees: Coopers Animal Health NZ Ltd., University of Melbourne, Ministry of Agriculture & Fisheries
    Inventors: Gavin B. L. Harrison, Robert P. Dempster, Michael D. Rickard, Marshall W. Lightowlers, Kim L. O'Hoy, Kevin S. Johnson, David D. Heath, Stephen B. Lawrence, Jennifer G. Vinton
  • Patent number: 5312810
    Abstract: Compositions comprising the C-terminal portion of adenylate cyclase stimulating factor (ACSF) are useful for making ACSF-specific antisera.
    Type: Grant
    Filed: November 13, 1992
    Date of Patent: May 17, 1994
    Assignees: The University of Melbourne, Genentech, Inc.
    Inventors: William I. Wood, Thomas J. Martin
  • Patent number: 5310551
    Abstract: A method for inhibiting pulmonary oxygen toxicity in a patient requiring elevated levels of inhaled oxygen, by prophylactic administration of certain adhesion molecules and antibodies thereto.
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: May 10, 1994
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Craig D. Wegner, L. Gordon Letts
  • Patent number: 5284931
    Abstract: Pharmaceutical compositions comprising antibodies to intercellular adhesion molecule-1 (ICAM-1 or CD54) are useful in methods of decreasing the severity of inflammation associated with the adhesion of leukocytes to cells bearing ICAM-1. Treatment with anti-ICAM-1 antibodies reduced the severity of inflammation associated with acute organ or tissue rejection and prolonged allograft survival time. Such compositions may optionally contain other immunsuppressive agents.
    Type: Grant
    Filed: April 27, 1990
    Date of Patent: February 8, 1994
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Patent number: 5159063
    Abstract: A substantially pure, single chain plasma protein of approximately 120 kDa having an N-terminal amino acid sequence EKNGIDIYSLTD, and a mixture of protein fragments having vasodilatory activity which fragments are generated by activated Kallikrein cleavage of the 120 kDa protein.
    Type: Grant
    Filed: February 2, 1989
    Date of Patent: October 27, 1992
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Carl H. Hammer, Ruth M. Jacobs, Michael M. Frank
  • Patent number: 5019511
    Abstract: Monoclonal antibodies are disclosed that react with an antigenic polypeptide having a molecular weight of approximately 45,000 that is expressed in the cell membrane of P. falciparun-infected erythrocytes. The antibodies were raised using the Honduras CDC isolate, and can be used for diagnostic purposes. The hybridoma producing the monoclonal antibodies is also disclosed.
    Type: Grant
    Filed: April 14, 1988
    Date of Patent: May 28, 1991
    Inventors: Robert T. Reese, Harold A. Stanley